Next Article in Journal
Motivation to Consent and Adhere to the FORT Randomized Controlled Trial
Next Article in Special Issue
Innovations in the Management of Vaginal Cancer
Previous Article in Journal
DTI Abnormalities Related to Glioblastoma: A Prospective Comparative Study with Metastasis and Healthy Subjects
Previous Article in Special Issue
Comparison of Prognosis between Minimally Invasive and Abdominal Radical Hysterectomy for Patients with Early-Stage Cervical Cancer
 
 
Review
Peer-Review Record

New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review

Curr. Oncol. 2022, 29(4), 2835-2847; https://doi.org/10.3390/curroncol29040231
by Adelina Silvana Gheorghe 1,*,†, Elena Adriana Dumitrescu 1,†, Isabela Anda Komporaly 1, Raluca Ioana Mihăilă 1, Cristian Virgil Lungulescu 2 and Dana Lucia Stănculeanu 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Curr. Oncol. 2022, 29(4), 2835-2847; https://doi.org/10.3390/curroncol29040231
Submission received: 31 January 2022 / Revised: 19 March 2022 / Accepted: 6 April 2022 / Published: 17 April 2022
(This article belongs to the Special Issue New Frontiers in Treatment for Gynecologic Cancers)

Round 1

Reviewer 1 Report

This is a very comprehensive review of the last advances in the field, which could be very useful for researchers. Nevertheless, I suggest further checking of references, to verify that referencing is correct. I also propose to report data consistently: include same/similar data for each study (for instance, in some cases study population or dosages are reported, but not in other). Additionally, subsections could be helpful. Further notes are indicated in the pdf.

Comments for author File: Comments.pdf

Author Response

Dear Reviewer,

Thank you very much for your time, for all the recommended changes and especially for the highlights in the pdf. We addressed the issues mentioned in the pdf, less the recommendation to subdivide the PARP inhibitors because there is only one paragraph written regarding some of the drugs.

We modified the bibliography and checked for accuracy. We also deleted the doses, because there was inconsistency in reporting them (not in all studies).

Kind regards, on behalf of all authors,

Dr. Adelina Silvana Gheorghe

Reviewer 2 Report

This is a comprehensive work summarizing the key findings of studies concerning targeted therapy in the most common gynecological cancers presented on major gynecologic-oncological congresses in 2021. This is a simple approach with unavoidable limitations. However, within this framework, this is a useful overview which can be published.  I strongly recommend to improve the manuscript by summarizing the key findings in tables.

Author Response

Dear Reviewer,

Thank you very much for your time and kind words.

We have changed the manuscript in many aspects, including language, corrections of data inaccuracy and references.

Except for the table that already existed in the article, we sincerely do not know how a table could improve the understanding of the data. We hope that it is not an impediment.

Kind regards, on behalf of all authors,

Dr. Adelina Silvana Gheorghe

Back to TopTop